109 related articles for article (PubMed ID: 21393040)
1. Combined Hurler and Sanfilippo syndrome in a sibling pair.
Sun A; Hopwood JJ; Thompson J; Cederbaum SD
Mol Genet Metab; 2011 Jun; 103(2):135-7. PubMed ID: 21393040
[TBL] [Abstract][Full Text] [Related]
2. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.
Hampe CS; Wesley J; Lund TC; Orchard PJ; Polgreen LE; Eisengart JB; McLoon LK; Cureoglu S; Schachern P; McIvor RS
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33572941
[TBL] [Abstract][Full Text] [Related]
3. Late-onset mucopolysaccharidosis type IIIA mimicking Usher syndrome.
De Falco A; Karali M; Criscuolo C; Testa F; Barillari MR; Scarpato M; Gaudieri V; Cuocolo A; Russo A; Nigro V; Simonelli F; Banfi S; Brunetti-Pierri N
Am J Med Genet A; 2024 May; 194(5):e63517. PubMed ID: 38149346
[TBL] [Abstract][Full Text] [Related]
4. Mucopolysaccharidosis III (Sanfilippo Syndrome)- disease presentation and experimental therapies.
Gilkes JA; Heldermon CD
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():133-40. PubMed ID: 25345095
[TBL] [Abstract][Full Text] [Related]
5. Hurler disease (mucopolysaccharidosis type IH): clinical features and consanguinity in Tunisian population.
Chkioua L; Khedhiri S; Ben Turkia H; Chahed H; Ferchichi S; Ben Dridi MF; Laradi S; Miled A
Diagn Pathol; 2011 Nov; 6():113. PubMed ID: 22074387
[TBL] [Abstract][Full Text] [Related]
6. Triamterene Functions as an Effective Nonsense Suppression Agent for MPS I-H (Hurler Syndrome).
Siddiqui A; Dundar H; Sharma J; Kaczmarczyk A; Echols J; Dai Y; Sun CR; Du M; Liu Z; Zhao R; Wood T; Sanders S; Rasmussen L; Bostwick JR; Augelli-Szafran C; Suto M; Rowe SM; Bedwell DM; Keeling KM
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901952
[TBL] [Abstract][Full Text] [Related]
7. Growth patterns for untreated individuals with MPS I: Report from the international MPS I registry.
Viskochil D; Clarke LA; Bay L; Keenan H; Muenzer J; Guffon N
Am J Med Genet A; 2019 Dec; 179(12):2425-2432. PubMed ID: 31639289
[TBL] [Abstract][Full Text] [Related]
8. Sanfilippo Syndrome: Molecular Basis, Disease Models and Therapeutic Approaches.
Benetó N; Vilageliu L; Grinberg D; Canals I
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105639
[TBL] [Abstract][Full Text] [Related]
9. Klüver-Bucy syndrome associated with a recessive variant in HGSNAT in two siblings with Mucopolysaccharidosis type IIIC (Sanfilippo C).
Hu H; Hübner C; Lukacs Z; Musante L; Gill E; Wienker TF; Ropers HH; Knierim E; Schuelke M
Eur J Hum Genet; 2017 Feb; 25(2):253-256. PubMed ID: 27827379
[TBL] [Abstract][Full Text] [Related]
10. A novel mutation of SGSH and clinical features analysis of mucopolysaccharidosis type IIIA.
Li X; Xiao R; Chen B; Yang G; Zhang X; Fu Z; Fu J; Zhuang M; Huang Y
Medicine (Baltimore); 2018 Dec; 97(52):e13758. PubMed ID: 30593151
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison.
Eisengart JB; Rudser KD; Xue Y; Orchard P; Miller W; Lund T; Van der Ploeg A; Mercer J; Jones S; Mengel KE; Gökce S; Guffon N; Giugliani R; de Souza CFM; Shapiro EG; Whitley CB
Genet Med; 2018 Nov; 20(11):1423-1429. PubMed ID: 29517765
[TBL] [Abstract][Full Text] [Related]
12. Novel therapies for mucopolysaccharidosis type III.
Seker Yilmaz B; Davison J; Jones SA; Baruteau J
J Inherit Metab Dis; 2021 Jan; 44(1):129-147. PubMed ID: 32944950
[TBL] [Abstract][Full Text] [Related]
13. Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment.
Shapiro EG; Nestrasil I; Rudser K; Delaney K; Kovac V; Ahmed A; Yund B; Orchard PJ; Eisengart J; Niklason GR; Raiman J; Mamak E; Cowan MJ; Bailey-Olson M; Harmatz P; Shankar SP; Cagle S; Ali N; Steiner RD; Wozniak J; Lim KO; Whitley CB
Mol Genet Metab; 2015; 116(1-2):61-8. PubMed ID: 26095521
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of novel genetic variants in the first Chinese family of mucopolysaccharidosis IIIC (Sanfilippo C syndrome).
Zhao H; Wang L; Zhang M; Wang H; Zhang S; Wu J; Tang Y
J Cell Mol Med; 2024 Apr; 28(8):e18307. PubMed ID: 38613342
[TBL] [Abstract][Full Text] [Related]
15. The attenuated end of the phenotypic spectrum in MPS III: from late-onset stable cognitive impairment to a non-neuronopathic phenotype.
Nijmeijer SCM; van den Born LI; Kievit AJA; Stepien KM; Langendonk J; Marchal JP; Roosing S; Wijburg FA; Wagenmakers MAEM
Orphanet J Rare Dis; 2019 Nov; 14(1):249. PubMed ID: 31718697
[TBL] [Abstract][Full Text] [Related]
16. Child Neurology: Mucopolysaccharidosis IIID: Evidence From Ultrastructural and Genomic Study.
Santhoshkumar R; Mahale RR; Kishore PK; Chickabasaviah YT
Neurology; 2023 Oct; 101(15):e1572-e1576. PubMed ID: 37487748
[TBL] [Abstract][Full Text] [Related]
17. Clinical, biochemical, and molecular characterization of mucopolysaccharidosis type III in 34 Egyptian patients.
Almenabawy N; Ramadan M; Kamel M; Mahmoud IG; Amer F; Shaheen Y; Elnaggar W; Selim L
Am J Med Genet A; 2023 Sep; 191(9):2354-2363. PubMed ID: 37596900
[TBL] [Abstract][Full Text] [Related]
18. [Natural history of mucopolysaccharidosis type III in a series of Colombian patients].
Cabarcas L; Ramón JL; Espinosa E; Guerrero GP; Martínez N; Santamaría N; Lince I; Reyes S
Rev Neurol; 2024 Mar; 78(6):171-177. PubMed ID: 38482704
[TBL] [Abstract][Full Text] [Related]
19. An immune deficient mouse model for mucopolysaccharidosis IIIA (Sanfilippo syndrome).
Pollock K; Noritake S; Imai DM; Pastenkos G; Olson M; Cary W; Yang S; Fierro FA; White J; Graham J; Dahlenburg H; Johe K; Nolta JA
Sci Rep; 2023 Oct; 13(1):18439. PubMed ID: 37891179
[TBL] [Abstract][Full Text] [Related]
20. Whole genome sequencing for mutation discovery in a single case of lysosomal storage disease (MPS type 1) in the dog.
Mansour TA; Woolard KD; Vernau KL; Ancona DM; Thomasy SM; Sebbag L; Moore BA; Knipe MF; Seada HA; Cowan TM; Aguilar M; Titus Brown C; Bannasch DL
Sci Rep; 2020 Apr; 10(1):6558. PubMed ID: 32300136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
